Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is not a good read. It's misleading trash as always from insiderfinancial and Chris Sandburg. None of his predictions for over a year has ever happened.
That's paid stock promotion.
You must hate europe. They need something that works, not leronlimab.
The study failed in all endpoints.
84% of the study are still completely hidden by Cytodyn.
Post-hoc subgroup data-mining is fraud.
short volume ratio 86%
Looks bad. Could that have been insiders?
Cytodyn SEC Form 144
Approximate Date of Sale 02/01/2021
Yes, but:
As of November 30, 2020, the Company has recorded current liabilities of approximately $44 million and long-term liabilities of $34 million related to inventory manufactured pursuant to the Samsung Agreement.
10K WTF ?
Note 11. Private Securities Offerings
On October 14, 2020, the Company entered into privately negotiated warrant exchange agreements with certain accredited investors, pursuant towhich
the investors purchased common stock at a range of $0.24 to $0.80 per share in exchange for warrants with an exercise price ranging from $0.30 to $1.00
per share of common stock. The Company issued approximately 7.0 million shares of common stock, $0.001 par value, in exchange for approximately
6.4 million warrants to purchase common stock, which resulted in net aggregate proceeds of approximately $2.7 million. In connection with this
transaction, the Company recognized approximately $2.2 million of non-cash inducement interest expense.On October 26, 2020, the Company entered into privately negotiated warrant exchange agreements with certain accredited investors, pursuant towhich
the investors purchased common stock at a range of $0.24 to $0.60 per share in exchange for warrants with an exercise price ranging from $0.30 to $0.75
per share of common stock. The Company issued approximately 5.0 million shares of common stock, $0.001 par value, in exchange for approximately
4.5 million warrants to purchase common stock, which resulted in net aggregate proceeds of approximately $1.6 million. In connection with this
transaction, the Company recognized approximately $1.4 million of non-cash inducement interest expense.
On November 17, 2020, the Company conducted a private equity offering, in which an accredited investor purchased unregistered common stock at 1$.50
per share. Pursuant to the offering, the Company sold approximately 0.67 million shares of common stock, $0.001 par value, for aggregate proceeds of
$1.0 million.
On November 30, 2020, the Company entered into a privately negotiated warrant exchange agreements with certain accredited investors, pursuant to which
the investors purchased common stock at $0.60 per share in exchange for warrants with an exercise price of$0.75 per share of common stock. The
Company issued approximately 0.5 million shares of common stock, $0.001 par value, in exchange for0.5 million warrants to purchase common stock,
which resulted in net aggregate proceeds of approximately $0.3 million.
That would require a mortality of at least 30% in the placebo group if there are no more additional deaths.
But the soc-mortality rate severe is around 10% and critical 25%.
I have the impression that there is more truth in this than in Cytodyn's press releases.
Why ? What´s the problem with it ?
3 billion $ joke of the year.
Only promises to dump shares, but no results.
Wake up !
Market Cap 3 billion $ without any evidence and the insiders dumping their stocks.
Stupid
eIND Timeline
How easy
If covid doesn't work, as the mortality suggests, they'll go bankrupt I believe. The last funding was a disaster.
No HIV BLA for US? Is Nader kidding us?
Mortality rates
Why is the death rate in the cydy study (23%) even worse than that of ICU patients (20%)?
How meaningful is NEWS2 in a m2m study ?
NEWS (or NEWS2) score when assessing possible COVID-19 patients in primary care?
There is no research on the value of these tools for COVID-19 outside Hospital
an further
Enthusiasm for NEWS2 in the primary care management of COVID-19 may be premature. If used at all, this score should be used alongside a wider clinical assessment of the patient and in the context of changes over time.
What do you think ?
I'm sorry, but I cannot see any physical benefit to the patients in the study.
Maybe I'm blind.
Where do I find it?
Why did NP sell exactly 1% of the outstanding shares?
Is there a threshold for reporting?
Did he want to hide the sale?